SLC5A2 and urinary tract infection: SGLT2 inhibitors are associated with a wide variety of metabolic andcardiorenal benefits and are included in numerous clinical practiceguidelines.32,111 Despite being generally well tolerated, adverseevents associated with SGLT2 inhibitors can include genital mycoticinfections (GMIs), urinary tract infections (UTIs), possible risk ofamputation, and diabetic ketoacidosis (DKA).112